Patients with LBCL who are refractory to first-line therapy or relapsed ≤1 year after first-line therapy initiation have poor outcomes with the current standard-of-care, consisting of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) [2-4]. The 3-year EFS rates are approximately 20% for this treatment [4].
Previous studies with liso-cel
Liso-cel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell product administered at an equal target dose of CD8+ and CD4+ CAR-positive T cells. “In the phase 1 TRANSCEND NHL 001 study (NCT02631044), liso-cel has demonstrated excellent efficacy and manageable safety in patients with R/R LBCL after ≥2 prior lines of therapy,” said Dr Manali Kamdar (University of Colorado Cancer Center, Denver, USA). Liso-cel treatment resulted in an objective response rate (ORR) of 83%, with a CR rate of 53%. In addition, few grade ≥3 cytokine release syndrome (CRS) or neurological events were reported [5].
Liso-cel versus standard-of-care
Dr Kamdar presented a prespecified interim analysis of the phase 3 TRANSFORM study (NCT03575351) evaluating the efficacy and safety of liso-cel versus standard-of-care as second-line therapy in patients with R/R LBCL. The results showed that median EFS and median PFS were significantly longer in patients receiving liso-cel. Moreover, the CR rate was significantly higher in the liso-cel arm compared with the standard-of-care arm (see Table 1).

After a median follow-up of 6.2 months (range 0.9–20.0), median OS was not achieved. However, a numerical trend favoured the liso-cel arm over the standard-of-care arm (HR 0.509; 95% CI 0.258–1.004; P=0.0257).
Safety profile
Safety results in the second-line setting were consistent with the liso-cel safety profile in the third-line or later. No new safety signals of liso-cel were detected in the current study. In the liso-cel arm, any-grade CRS was reported in 49% of patients, with grade 1 in 37% and grade 2 in 11%. Only 1 patient experienced a grade 3 CRS event.
Any-grade neurological events were reported in 12% of the patients. These events were primarily low-grade events, with only 4% of the patients demonstrating a grade3 event. No grade 4 or 5 CRS or neurological events were reported.
Conclusions
In the TRANSFORM study, liso-cel demonstrated superiority over salvage chemotherapy followed by high-dose chemotherapy and ASCT (standard of care), with highly significant and clinically meaningful improvement in EFS, CR rate and PFS as second-line therapy in patients with LBCL primary refractory to or relapsed ≤1 year after first-line therapy. In addition to the improved outcomes, liso-cel exhibited a favourable safety profile.
- Kamdar M, et al. Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study. Abstract 91, ASH 2021 Annual Meeting, 11-14 Dec.
- Crump M, et al. J Clin Oncol. 2014;32:3490-6.
- van Imhoff GW, et al. J Clin Oncol. 2017;35:544-551.
- Gisselbrecht C, et al. J Clin Oncol. 2010;28:4184-90.
- Abramson JS, et al. Abstract 91, ASH 2021 Annual Meeting, 11-14 Dec.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL Next Article
Lifelong patterns of clonal haematopoiesis revealed »
« CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL Next Article
Lifelong patterns of clonal haematopoiesis revealed »
Table of Contents: ASH 2021 Focus on CAR T-Cell Therapy
Featured articles
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
CAR T-cell Therapy
Most re-hospitalisations within first month from CAR T-cell infusion
CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL
High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL
Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma
CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL
Improved QoL with axi-cel versus standard-of-care in R/R LBCL
Related Articles
February 8, 2021
Burkitt lymphoma prognostic index may lead to more targeted therapy
November 26, 2020
B-cell lymphoma might respond to N-myristoyltransferase inhibition
September 9, 2020
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy